TAZVERIK® (Tazemetostat)

The FDA on June 18, 2020 granted accelerated approval to TAZVERIK®, an EZH2 inhibitor, for adult patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. TAZVERIK® is a product of Epizyme, Inc.